Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GDD3898
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Alethea Capital
Deal Size : $20.0 million
Deal Type : Series A Financing
Details : GDD3898, is in development for the treatment of several conditions associated with excess body fat, including moderate to severe acne and sebaceous hyperplasia, nonalcoholic steatohepatitis (NASH), and obesity.
Product Name : GDD3898
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 11, 2022
Lead Product(s) : GDD3898
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Alethea Capital
Deal Size : $20.0 million
Deal Type : Series A Financing
Lead Product(s) : GDD3898
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Maxim Merchant Capital
Deal Size : Undisclosed
Deal Type : Series A Financing
Lipidio Pharmaceuticals Launches with First Close of Series A Financing
Details : The financing will support the development of its lead therapeutic candidate GDD3898.
Product Name : GDD3898
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 03, 2020
Lead Product(s) : GDD3898
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Maxim Merchant Capital
Deal Size : Undisclosed
Deal Type : Series A Financing